More than 224,000 clinical studies are registered on the NIH's ClinicalTrials.gov website. Just over 10% of these studies, some 23,000 entries, also list clinical trial results. The FDA and NIH have now released new rules to boost the reporting of summary results for trials that fall under their purview. Deborah Zarin, director of ClinicalTrials.gov, welcomes these changes as a means of shoring up the quality of the global clinical research enterprise. She spoke with Asher Mullard about the new rules, penalties for non-compliance and the importance of individual participant data.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Deborah Zarin. Nat Rev Drug Discov 15, 742–743 (2016). https://doi.org/10.1038/nrd.2016.215
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2016.215
